We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




LDH Levels Could Predict Kidney Cancer Response to Treatment

By LabMedica International staff writers
Posted on 22 Aug 2012
A common enzyme that is easily detected in blood may predict how well patients with advanced kidney cancer will respond to a specific treatment.

In kidney cancer, elevated lactate dehydrogenase (LDH) levels were considered a risk factor for aggressive disease, signaling tumor progression. More...
Recent studies suggest that elevated LDH may also indicate the activation of key genetic alterations that lead to cancer proliferation. One of these cancer gene pathways relies on a protein called mammalian target of rapamycin, or mTOR, and drugs that are mTOR inhibitors work to shut down the process.

Andrew Armstrong, MD, ScM, associate professor of medicine and surgery at Duke University Medical Center (Durham, NC, USA) and colleagues at Duke analyzed the outcomes of 404 study participants, approximately half of whom received a standard therapy, interferon-alpha, and half who received temsirolimus, a mTOR inhibitor, which has been approved by the US Food and Drug Administration to treat kidney cancer. LDH levels had been measured at the start of the study for all participants.

Patients with high LDH levels at the start of the study survived significantly longer on the mTOR inhibitor drug than they did on interferon-alpha. Median survival for patients with high LDH levels was 6.9 months on temsirolimus compared to 4.2 months for the high LDH level patients on the standard drug. At six months, 53.7% of high LDH level patients taking temsirolimus were alive, compared to 39.5% taking interferon-alpha. Patient survival rates at 12 months were 34.3 percent for temsirolimus, vs. 12.7% for interferon-alpha.

Prof. Armstrong, lead author of the study, said that the study statistically proves that LDH is a predictive biomarker for advanced renal cell carcinoma (RCC), but the results have to be validated before major practice changes take place.

"The advantage of LDH as a predictive and prognostic biomarker rests in its ease of collection, cost, and its routine assessment as part of routine medical care in patients with RCC," the authors wrote.

Related Links:

Duke University Medical Center




Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Specimen Radiography System
TrueView 200 Pro
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.